Paragon: Reforming Policies That Drive Hospital Costs Key To Tackling Health Spending

Why It Matters

Hospital cost inflation erodes employer and consumer budgets, while policy reforms could restore competition and lower prices. The report highlights a clear legislative pathway that, if enacted, would reshape the financial dynamics of U.S. health care.

Key Takeaways

• Hospital prices rise 4% annually, outpacing inflation
• Site‑neutral payment reforms could cut inpatient margins by 10%
• 340B drug discount program reforms target $30 billion savings
• Hospital lobby opposes changes despite bipartisan congressional support
• Paragon's 12‑point plan aims to restore competition

Pulse Analysis

Government reimbursement rules, from Medicare’s prospective‑payment system to the 340B drug discount program, have unintentionally encouraged hospital consolidation. By rewarding larger facilities with higher rates and allowing them to leverage economies of scale, these policies have reduced competition and pushed average inpatient charges upward by roughly 4% each year—well above overall inflation. Analysts argue that the structural incentives embedded in current payment models are a hidden tax on patients and payers alike.

Paragon’s 12‑point blueprint tackles the root causes. Site‑neutral payment reforms would level reimbursement across hospital settings, stripping away the premium paid to inpatient beds and nudging providers toward more efficient outpatient care. Simultaneously, tightening 340B eligibility and pricing rules could unlock up to $30 billion in drug‑cost savings nationwide. Both proposals have attracted bipartisan interest, yet the powerful hospital lobby has blocked legislative momentum, citing concerns over financial stability and access. The think‑tank’s report underscores that political will, not technical feasibility, is the primary barrier.

If lawmakers adopt Paragon’s recommendations, insurers, employers, and consumers could see a measurable slowdown in health‑care cost growth. Restored competition would likely drive down negotiated rates, improve price transparency, and reduce the incentive for further consolidation. For providers, the shift would demand operational agility and a focus on value‑based care rather than volume. The report therefore serves as a strategic roadmap for stakeholders seeking to influence the next wave of health‑policy reform before the 2028 election cycle intensifies the debate over health‑spending caps.